[HTML][HTML] Erlotinib at a dose of 25 mg daily for non-small cell lung cancers with EGFR mutations
Purpose The tyrosine kinase inhibitors (TKIs) gefitinib and erlotinib are effective in non-small
cell lung cancers (NSCLCs) with epidermal growth factor receptor (EGFR) gene mutations …
cell lung cancers (NSCLCs) with epidermal growth factor receptor (EGFR) gene mutations …
The efficacy of first-line tyrosine kinase inhibitors combined with co-medications in Asian patients with EGFR mutation non-small cell lung cancer
The real-world efficacy of epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors
(TKIs) in patients with advanced non-small cell lung cancer (NSCLC) harboring EGFR …
(TKIs) in patients with advanced non-small cell lung cancer (NSCLC) harboring EGFR …
Smoking History as a Predictor of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients with Non-Small Cell Lung Cancer Harboring EGFR …
N Nishinarita, S Igawa, M Kasajima, S Kusuhara… - Oncology, 2018 - karger.com
Background: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKIs)
therapy has been recognized as the standard treatment for patients with non-small cell lung …
therapy has been recognized as the standard treatment for patients with non-small cell lung …
Predictors of outcome for patients with lung adenocarcinoma carrying the epidermal growth factor receptor mutation receiving 1st-line tyrosine kinase inhibitors …
S Pilotto, M Di Maio, U Peretti, S Kinspergher… - Critical Reviews in …, 2014 - Elsevier
Purpose We performed a sensitivity and meta-regression analysis, cumulating all
randomized trials exploring the benefit of afatinib, erlotinib and gefitinib versus …
randomized trials exploring the benefit of afatinib, erlotinib and gefitinib versus …
Comparison of adverse events and efficacy between gefitinib and erlotinib in patients with non-small-cell lung cancer: a retrospective analysis
T Yoshida, K Yamada, K Azuma, A Kawahara, H Abe… - Medical oncology, 2013 - Springer
Previous studies have demonstrated that both gefitinib and erlotinib are markedly effective
for the treatment of non-small-cell lung cancer (NSCLC) with somatic activating mutations of …
for the treatment of non-small-cell lung cancer (NSCLC) with somatic activating mutations of …
Which tyrosine kinase inhibitor should be recommended as initial treatment for non-small cell lung cancer patients with EGFR mutations?
A Tartarone, R Lerose, C Lazzari, V Gregorc, M Aieta - Medical Oncology, 2014 - Springer
Non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR)
mutations derive greater benefits from first-and second-generation tyrosine kinase inhibitors …
mutations derive greater benefits from first-and second-generation tyrosine kinase inhibitors …
Impact of epidermal growth factor receptor gene expression level on clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients …
HC Chang, YM Chen, CC Tseng, KT Huang… - Tumor …, 2017 - journals.sagepub.com
Epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) are first-choice
treatments for advanced non-small-cell lung cancer patients harboring EGFR mutations …
treatments for advanced non-small-cell lung cancer patients harboring EGFR mutations …
Cost-effectiveness and safety of the molecular targeted drugs afatinib, gefitinib and erlotinib as first-line treatments for patients with advanced EGFR mutation-positive …
M Kimura, F Yasue, E Usami… - Molecular and …, 2018 - spandidos-publications.com
Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs), including gefitinib,
erlotinib and afatinib are standard first-line treatments for EGFR gene mutation-positive non …
erlotinib and afatinib are standard first-line treatments for EGFR gene mutation-positive non …
Clinical significance of erlotinib monotherapy for gefitinib-resistant non-small cell lung cancer with EGFR mutations
N Koyama, Y Uchida - Anticancer Research, 2013 - ar.iiarjournals.org
Background: The efficacy of the epidermal growth factor receptor (EGFR) tyrosine kinase
inhibitor (TKI) erlotinib is difficult to be accurately assessed in patients with non-small cell …
inhibitor (TKI) erlotinib is difficult to be accurately assessed in patients with non-small cell …
Impact of smoking history on the efficacy of gefitinib in patients with non-small cell lung cancer harboring activating epidermal growth factor receptor mutations
S Igawa, J Sasaki, S Otani, M Ishihara, A Takakura… - Oncology, 2015 - karger.com
Background: Gefitinib treatment has come to be recognized as the standard therapy for
patients with non-small cell lung cancer (NSCLC) harboring epidermal growth factor …
patients with non-small cell lung cancer (NSCLC) harboring epidermal growth factor …